Work

139P First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD) study of IOA-244, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in patients with advanced metastatic mesothelioma, uveal and cutaneous melanoma

Year: 2021

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.10.158

Authors: A.M. Di Giacomo, F. Santangelo, G. Amato, E. Simonetti, J. Graham, M. Lahn, R. Zorilla, L. van der Veen, Z. Johnson, C. Pickering, E. Maréchal, J. Blanco, M. Durini, B. Gufford, T. Lakshmikanth, P. Brodin, P. Spiliopoulou, T.R.J. Evans, M. Maio

Institutions: Azienda Ospedaliera Universitaria Senese, NHS Greater Glasgow and Clyde, Beatson West of Scotland Cancer Centre, iOnctura SA (Switzerland), LabCorp (United States), Karolinska Institutet, University of Glasgow

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4200437806

FWCI: 0.399

Cites:

Cited by: 5

Related to: 10